SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-23-003248
Filing Date
2023-02-01
Accepted
2023-02-01 08:45:42
Documents
17
Period of Report
2023-01-27
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 38363
2 ex99-1.htm EX-99.1 36873
3 ex99-2.htm EX-99.2 21266
4 ex99-3.htm EX-99.3 917
5 ex99-1_001.jpg GRAPHIC 5751
6 ex99-3_001.jpg GRAPHIC 305588
  Complete submission text file 0001493152-23-003248.txt   712625

Data Files

Seq Description Document Type Size
7 XBRL SCHEMA FILE rspi-20230127.xsd EX-101.SCH 3230
8 XBRL LABEL FILE rspi-20230127_lab.xml EX-101.LAB 34240
9 XBRL PRESENTATION FILE rspi-20230127_pre.xml EX-101.PRE 22361
11 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3332
Mailing Address 126 VALLEY ROAD SUITE C GLEN ROCK NJ 07452
Business Address 126 VALLEY ROAD SUITE C GLEN ROCK NJ 07452 (201) 444-4947
RespireRx Pharmaceuticals Inc. (Filer) CIK: 0000849636 (see all company filings)

IRS No.: 330303583 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-16467 | Film No.: 23574849
SIC: 2834 Pharmaceutical Preparations